CT-INTERACTIVE-BROKERS
28.2.2023 16:01:43 CET | Business Wire | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of its revamped IBKR Campus website, providing a comprehensive set of free educational resources to all levels of investors. IBKR Campus includes courses, webinars, podcasts, and market commentaries to help investors learn about trading, financial markets, and Interactive Brokers' trading tools.
The revamped IBKR Campus is simple to use, enabling investors to easily find what they are looking for. Beginning investors, as well as advanced traders, will find information to sharpen their skills and broaden their investment horizons. From free online courses on the concepts and tools of financial trading to lessons and quizzes on Interactive Brokers' trading tools, all investors can take advantage of these resources to become better investors. IBKR Campus also features commentaries from Steve Sosnick, Chief Strategist at Interactive Brokers, and José Torres, Senior Economist at Interactive Brokers, discussing themes impacting the markets and economy globally.
Steve Sanders, EVP of Marketing and Product Development at Interactive Brokers, emphasized the significance of education for IBKR, stating, "Education is at the heart of Interactive Brokers, and we firmly believe that knowledge is key to successful investing. With the user-friendly IBKR Campus site, we are empowering investors globally to stay informed about market events, improve their market understanding, and continuously develop their skills."
IBKR Campus services are available at no cost to both clients and non-clients globally. For the full suite of IBKR Campus resources, please see below and visit https://ibkrcampus.com/
Traders’ Academy: Investors can access free learning modules focused on IBKR’s trading tools at a pace that suits them. Newcomers can browse stock trading education, while more advanced students can take advantage of options trading education.
Traders’ Insight: Investors can review market-related articles, videos, and podcasts covering current financial market and economic events happening around the world. With market commentary from leading financial institutions, as well as from Interactive Brokers’ experts, daily insights explore catalysts impacting asset classes and markets worldwide.
IBKR Quant: Popular with computational finance students as well as those wanting to trade markets using computer power, articles are contributed by coders and developers in the quant space and seek to help programmers with concise and actionable code-based information.
IBKR Podcasts: Investors can listen to interviews and episodes with executives and researchers from prominent financial services companies examining topical themes impacting markets and trading including a recent podcast in which Steve Sosnick and José Torres assess the impact of monetary policy and recent economic data releases: Black Eye for Bond Bulls Gives Equity Traders a Headache
IBKR Webinars: Contributors explore market-related topics weekly, such as options trading, commodities, ETFs, volatility, and more.
Traders’ Glossary: Lets investors search for terms and definitions related to trading and investing, from products and order types to specific information about Interactive Brokers’ platforms, and offers suggestions for related terms and links.
Student Trading Lab: A free online resource for educators looking to blend finance or computer science classwork with real-world trading experiences. Students receive a paper trading account and can trade products across asset classes. The account equity fluctuates as if the trades were executed in the real market.
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities, and foreign exchange around the clock on over 150 markets in numerous countries and currencies, from a single unified platform to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. For the fifth consecutive year, Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its March 25, 2022, Best Online Brokers Review.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005260/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom